David Ege

David Ege has more than 20 years of experience in the pharmaceutical industry, with a focus in biologics, vaccines and novel modalities.
Prior to joining ADCT in 2024, Dr. Ege was CTO, head of Process Development, Quality and Supply at Seres Therapeutics since 2020. He began his career at Merck in 2003, serving in a variety of technical, operations and leadership roles in R&D, manufacturing and supply chain, in the U.S. and Switzerland. He has contributed to the successful first-in-class licensure and launch of cervical cancer vaccines, Gardasil® (2006) and Gardasil9® (2014), the breakthrough cancer immunotherapy, Keytruda® (2014), and oral live microbiome therapy Vowst™ (2023). He graduated from Princeton with a BSE in chemical engineering and earned his PhD in chemical engineering from the University of Pennsylvania.